Mass tort lawsuit · Checked on November 3, 2026
Zantac lawsuit: status November 2026
This litigation is closed to new advertising on this site. The federal MDL court excluded the plaintiffs' experts in 2022 and that ruling is on appeal, and a Delaware court granted summary judgment in April 2026 on the cases filed there (verified, GSK SEC filing). Plaintiffs allege ranitidine caused several cancers.
| Case | MDL 2924 |
|---|---|
| Court | U.S. District Court, Southern District of Florida (plus Delaware state court) |
| Judge | Robin L. Rosenberg |
| Pending cases | 806 (as of November 2, 2026) |
| Stage | Federal claims dismissed (on appeal); Delaware claims dismissed in April 2026 |
| New cases | Closed or settled; this page is for information only |
| Next scheduled date | None announced in the records we checked |
| Last checked | November 3, 2026 |
What plaintiffs allege
Plaintiffs allege that Zantac and other ranitidine products contained NDMA and caused bladder, stomach, esophageal, liver and pancreatic cancers. The manufacturers deny the claims.
Where the case stands
- Federal MDL 2924: plaintiffs' experts were excluded in December 2022; the Eleventh Circuit heard argument in October 2025 (reported).
- April 13, 2026: the Delaware Superior Court granted summary judgment for the defendants on cases filed on or before December 1, 2025 (verified, GSK SEC filing).
- GSK settled most of its cases in 2024 (reported).
Settlement status
GSK settled most of its cases in 2024 (reported). The remaining federal claims were dismissed and are on appeal, and the Delaware claims were dismissed in April 2026 (verified, GSK SEC filing).
Updates
Newest first. Each entry says whether we read the record ourselves (verified) or it comes from coverage (reported).
- November 2026: The federal panel's report of November 2, 2026 listed 806 pending cases (verified, JPML report).
- October 2026: The federal panel's report of October 1, 2026 listed 847 pending cases (verified, JPML report).
- April 2026: The Delaware Superior Court granted summary judgment for the defendants on April 13 (verified, GSK SEC filing).
- October 2025: The Eleventh Circuit heard argument on the federal expert ruling (reported).
Questions
Is the Zantac lawsuit real?
Yes. The U.S. Judicial Panel on Multidistrict Litigation listed 806 pending cases in MDL 2924 as of November 2, 2026 (verified). A pending case is a claim filed in court, not a finding that the claim is true.
When will the Zantac lawsuit settle?
Nobody can predict when or whether a mass tort will settle. What has been disclosed so far: GSK settled most of its cases in 2024 (reported). The remaining federal claims were dismissed and are on appeal, and the Delaware claims were dismissed in April 2026 (verified, GSK SEC filing).
Could Zantac claims come back?
Only if an appeals court reverses the earlier rulings. We will update this page if that happens.
Sources
- JPML, Pending MDL Dockets by Actions Pending, November 2, 2026 verified
- GSK Form 6-K filed with the SEC, 2026 verified
Verified means we read the court, agency or company record ourselves on the check date. Reported means the fact comes from news or law firm coverage and could not be confirmed on a primary record.